RecruitingNCT06081231

Open-Source Artificial Pancreas System Use Among People With Type 1 Diabetes Mellitus in China

The Safety and Efficacy of Open-Source Artificial Pancreas System Among People With Type 1 Diabetes Mellitus in China


Sponsor

Third Affiliated Hospital, Sun Yat-Sen University

Enrollment

500 participants

Start Date

Jan 1, 2019

Study Type

OBSERVATIONAL

Conditions

Summary

This real-world observational study aims to reveal the current status of the open-source artificial pancreas system (APS) use among people with T1DM in China and assess the glycemic efficacy and potential related factors of the open-source APS.


Eligibility

Min Age: 3 YearsMax Age: 75 Years

Inclusion Criteria4

  • diagnosed T1DM.
  • Currently use open-source APS for at least 3 months.
  • Willing and able to provide informed consent (or be a parent or other legally authorized representative) and to provide the data.
  • reside in China.

Exclusion Criteria1

  • None

Interventions

DEVICEopen-source APS;

a continuous glucose monitoring system, an insulin pump, and an intelligent algorithm.


Locations(1)

Jinhua Yan

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06081231


Related Trials